Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Clinical trial NCT07560488 · RECRUITING
Trial details
- NCT number
- NCT07560488
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-30
- Primary completion
- 2027-04-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.